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Higher incidence of diabetic nephropathy in type 2 than in detail [1–3]. Type 1 (insulin-dependent) diabetes mellitus
type 1 diabetes in early-onset diabetes in Japan. has been recognized as an important cause of diabetic
Background. Whether the type of diabetes, race, and year
nephropathy, leading to diabetic end-stage renal failureand age of diagnosis affect the incidence of diabetic vascular
(ESRF) and early death [4–7]. However, several reportscomplications is unknown. That both type 1 and type 2 diabetes
occur in the young Japanese population prompted us to investi- have identified an increasing incidence of ESRF in pa-
gate whether the type of diabetes and the year of diagnosis tients with type 2 (non–insulin-dependent) diabetes, es-
are related to the incidence of nephropathy.
pecially in minorities such as African Americans, Mexi-Methods. Of the 17,256 diabetic patients who visited the
can Americans, and Pima Indians [3, 8–14].outpatient clinic at our diabetes center between 1965 and 1990,
1578 (9.1%) had early-onset diabetes (diagnosed before the Ethnic differences likely lead to differing incidences
age of 30); of these, 620 (39%) had type 1, and 958 (61%) had of diabetes as well as differing incidences of the accompa-type 2 diabetes. The incidence of nephropathy was analyzed
nying vascular complications [3, 10, 12, 14]. Type 2 diabe-in the patients according to postpubertal duration and year of
diagnosis. tes is not rare in the young Japanese population [15, 16].
Results. The cumulative incidence of nephropathy after 30 We have recently reported that Japanese patients with
years of postpubertal diabetes was significantly higher (P ,
early-onset type 2 diabetes can develop severe diabetic0.0001) in type 2 diabetic patients (44.4%, 95% CI, 37.0 to
vascular complications, such as blindness or ESRF, when51.8%) than in type 1 diabetic patients (20.2%, 95% CI, 14.9
to 25.8%). The incidence of nephropathy among type 1 diabetic in their thirties [17]. On the other hand, a recent report
patients has declined during the past two decades, whereas it in young Swedish patients with type 1 diabetes indicatedhas not among type 2 diabetic patients. The rate ratio for type
a declining incidence of diabetic nephropathy [18], al-2 diabetic patients diagnosed between 1980 and 1984 relative
to type 1 diabetic patients diagnosed in the same period was though whether the decline is universally independent
2.74 (95% CI, 1.17 to 6.41). of ethnicity or nationality is a matter of debate [19, 20].
Conclusions. The incidence of nephropathy has declined in The incidence of diabetic ESRF is rising at a muchJapanese patients with type 1 but not in those with type 2
faster rate than ESRF because of all other etiologiesdiabetes. In young Japanese patients, because of the higher
incidence of nephropathy in type 2 diabetes and the higher worldwide [21, 22], that is, in the United States [23], in
prevalence of type 2 than type 1 diabetes, type 2 diabetes is some European countries [24], and in Japan [25]. The
likely the major cause of diabetic nephropathy.
progression to ESRF is relentless unless treated inter-
vention occurs not only for type 1 but also for type
2 diabetic patients [26, 27], and regular hemodialysisThe relationship of the type of diabetes to the risk of
treatment costs between $50,000 and $100,000 US perdiabetic vascular complications has not been studied in
person annually. The rising incidence of diabetic ESRF,
therefore, has prompted the re-evaluation of patients at
Key words: insulin-dependent diabetes, noninsulin-dependent diabe- risk for developing diabetic nephropathy according to
tes, childhood diabetes, end-stage renal failure, proteinuria, retinop-
race, type of diabetes, and year at diagnosis of diabetes.athy.
Because both types of diabetes occur in the young Japa-
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Fig. 1. Patient selection.
METHODS diabetes type, serum C-peptide levels were measured in
patients treated with insulin using a synthetic human C-Study population
peptide kit (C-PEPTIDE RIA; Shionogi, Tokyo, Japan).We performed a clinic-based epidemiologic observa-
The limit of detection of the kit was 0.1 ng/mL, andtional study. Patients can visit the outpatient clinic at the
interassay and intra-assay coefficients of variation wereDiabetes Center, Tokyo Women’s Medical University,
6.4 and 6.7%, respectively.without any referrals, and the charge for treatment paid
The patients visited the clinic every one to threeby the patient is the same as in the other hospitals. A
months (8 visits per annum on the average). Blood pres-large population of diabetic patients (N 5 17,256) who
sure was measured using a sphygmomanometer and anresided in the Tokyo metropolitan area (about 5400 km2)
appropriately sized cuff with the patient in a seated posi-attended the outpatient clinic between 1965 and 1990,
tion. Glycosylated hemoglobin (HbA1c) was measuredwhich corresponds to approximately 10% of diabetic
by high-performance liquid chromatography (HPLC;patients attending to a medical clinic in the metropolitan
HA8110; Kyoto Daiichi Kagaku, Kyoto, Japan). Thearea. Among them, 1638 (9.4%) had early-onset diabetes
normal range of HbA1c by HPLC was 4.8 to 6.4%. An(diagnosed before the age of 30; Fig. 1). Thirty-two early-
average of the HbA1c values during a year at first visitonset diabetic patients were excluded because they were
was calculated. For the patient who had no data onprepubertal (younger than 10 years old) at examination.
HbA1c at the first visit (before 1980, HbA1c measure-Eight patients were excluded because of coexisting non-
ment had not been instituted), the average of the firstdiabetic renal disease, and 20 patients were excluded
available year for HbA1c was used. Patient profiles re-because they already had nephropathy before their visits
garding the diagnosis of diabetes and medical treatmentto our clinic. Of the remaining 1578 (9.1%) patients with
to control the blood glucose level were compiled fromearly-onset diabetes, 620 (39%) with type 1 and 958
information obtained through interviews and data ob-(61%) with type 2 diabetes were included in the study.
tained from other hospitals attended by the patients.The proportion of male sex in each type was consistent
Data on the history of diabetes (any type of diabetes)with previous reports in a young Japanese diabetic popu-
in first-degree relatives were obtained from patients bylation [16, 17, 28].
interview.The diagnosis of diabetes and classification of diabetes
type (type 1 or type 2) was made according to the World
Outcome measuresHealth Organization criteria [29]. Briefly, type 1 diabetes
In accordance with suggestions by Parving et al, dia-was defined as the patient being prone to ketosis and
betic nephropathy was diagnosed clinically if the follow-requiring insulin therapy within one year after the diag-
ing criteria were fulfilled: persistent proteinuria, pres-nosis. Type 2 diabetes was diagnosed if the patient was
ence of diabetic retinopathy, and absence of clinical orfound not to be ketosis prone, did not require insulin
laboratory evidence of disease other than diabetic ne-therapy for more than one year after the diagnosis,
phropathy in the kidneys or renal tract [30]. Proteinuriaand/or exhibited preserved insulin secretion even when
was measured at each visit (every 1 to 3 months) usingtreated with insulin. Type 2 diabetes was diagnosed be-
Albustix (Miles-Sankyo, Tokyo, Japan), which has a de-cause of symptoms (27%), other complaints (28%), or
screening tests (45%). To confirm the diagnosis of the tection limit of 300 mg/L. The onset of proteinuria was
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Table 1. Clinical characteristics of patients with type 1 and type 2defined as the time when the first positive test was ob-
diabetes diagnosed before the age of 30tained.
Diabetes
Statistical analysis
Type 1 Type 2
Characteristic (N 5 620) (N 5 958)The incidence density and cumulative incidence were
used as measures of the frequency of diabetic nephropa- Male sex N of patients (%) 239 (39) 530 (55)
Calendar year at diagnosis of diabetesthy. The incidence density is presented as the number
N of patients (%)per 1000 person-years based on the ratio of the observed 1965–69 67 (11) 94 (10)
number of patients experiencing the event (cases) to the 1970–74 104 (17) 137 (14)
1975–79 137 (22) 195 (20)total person-years of exposure (at risk). The 95% CI was
1980–84 165 (26) 250 (26)
computed by a modification of the Mantel and Haenzel 1985–90 147 (24) 282 (30)
Age at diagnosis of diabetesprocedure for follow-up data [31–33]. The association of
N of patients (%)covariates with the risk of an event (developing diabetic
Diabetes diagnosed at 0–9 years 205 (33) 5 (1)
nephropathy) was assessed through the computation of Diabetes diagnosed at 10–19 years 257 (41) 278 (29)
Diabetes diagnosed at 20–29 years 158 (26) 675 (70)rates with stratification and regression models. Log-lin-
Age at first visitear Poisson regression models using SAS-GENMOD
Diabetes diagnosed at 0–9 years 15.466.2 20.167.8
were used to assess the effects of covariates on the abso- Diabetes diagnosed at 10–19 years 20.164.8 20.666.3
Diabetes diagnosed at 20–29 years 27.665.1 30.766.7lute risk and to estimate the cumulative incidence
Body mass index kg/m2 19.862.9 23.065.2[34–36]. A comparison of the incidence density with the HbA1c at first visit % 9.562.0 8.762.2
rate ratio was performed using the score chi-squared test, Systolic blood pressure at first visit
mm Hg 113612 117616and the normal approximation after log-transformation
Diastolic blood pressure at first visitwas used for the calculation of confidence intervals mm Hg 7169 74612
[33, 35]. The rate ratio was calculated by dividing the Diabetes in first-degree relatives %
(95% CI) 24 (21–27) 56 (53–59)incidence density of diabetic nephropathy in type 2 dia-
Therapy for diabetes at first visit
betic patients by that in type 1 diabetic patients. The N of patients (%)
Diet only 0 (0) 431 (45)cumulative incidence was plotted using the Kaplan–
Tablets 0 (0) 182 (19)Meier method with the log-rank test statistic.
Insulin 620 (100) 345 (36)
Person-years were primarily accumulated from the di- Serum C-peptide levels in insulin users
ng/mLagnosis of diabetes. The incidence density was calculated
Fastingfor five-year periods using two types of observation peri-
Mean 0.1 1.2
ods: the entire duration of diabetes and the postpubertal 95% CI 0–0.2 1.1–1.3
Two hours postprandialduration of diabetes. The observation based on postpu-
Mean 0.1 2.5bertal duration of diabetes is considered more relevant 95% CI 0–0.2 2.3–2.7
in this study since (1) the duration of diabetes before Age at final examination
Diabetes diagnosed at 0–9 years 24.667.7 29.267.3puberty does not contribute much to the risk of diabetic
Diabetes diagnosed at 10–19 years 29.666.5 27.668.1nephropathy [37–40], and (2) it can compensate for the Diabetes diagnosed at 20–29 years 37.267.0 38.569.0
considerable differences in age at diagnosis between type Postpubertal duration at examination
years 15.767.2 12.468.41 and type 2 diabetic patients. Patients who developed
Plus-minus values are mean 6 SD. CI denotes confidence interval.diabetes before the age of 10 years were entered into
the calculation of postpubertal diabetes when they
reached age 10. For patients who developed nephropa-
thy, the contribution of person-years was accumulated
personal computer using SPSS for Windows, version 6.0,until the year of onset of nephropathy. Those who re-
and SAS for Windows, version 6.11.mained free from nephropathy or those who deceased
without developing nephropathy contributed to person-
years until the last examination (the end of follow-up RESULTS
up to March 1997). Those who had no nephropathy and
Clinical features of patients with type 1 and type 2discontinued visits, presumably because they went out-
diabetes diagnosed before the age of 30side of the Tokyo area, contributed to person-years until
Clinical and biochemical characteristics of the patientsthe last clinic visit. Differences between relevant groups
with early onset diabetes are shown in Table 1. Thirty-were tested using the Student’s unpaired t-test for contin-
nine percent of the type 1 diabetic patients and 55% ofuous variables and the chi-squared test for dichotomized
the type 2 diabetic patients were male. The distributionvariables. P values under 5% (two-tailed) were taken to
indicate statistical significance. Analyses were run on a of patients according to the calendar year at diagnosis
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Table 2. Incidence density of diabetic nephropathy in patients with type 1 and type 2 diabetes diagnosed before the age of 30, by the
duration of diabetes and the postpubertal duration of diabetesa
Duration of diabetes years
0–4 5–9 10–14 15–19 20–24 251 Total
Duration of diabetes years
Type 1
N new cases 0 2 32 16 5 0 55
Person-years of duration 3009 2672 1898 1077 520 181 9357
Incidence density (/1000 person-years) 0 0.75 6.86 4.86 9.62 0 5.88
Type 2
N new cases 10 26 57 33 14 3 143
Person-years of duration 4034 3149 2012 1051 492 179 10917
Incidence density (/1000 person-years) 2.48 8.26 28.33 31.40 28.46 16.76 13.10
Rate ratiob
Type 2 vs. type 1 NC 11.01 1.68 2.11 2.96 NC 2.23
95% CI 2.61–46.4 1.09–2.59 1.10–3.54 1.07–8.22 1.63–3.04
P value 0.001 0.006 0.02 0.02 0.001
Postpubertal duration of diabetes years
Type 1
N new cases 0 6 31 14 4 0 55
Person-years of postpubertal duration 2938 2572 1720 867 365 99 8560
Incidence density (/1000 person-years) 0 2.33 18.02 16.15 10.96 0 6.43
Type 2
N new cases 10 26 57 33 14 3 143
Person-years of postpubertal duration 4034 3146 2012 1055 490 168 10905
Incidence density (/1000 person-years) 2.49 8.26 28.33 31.28 28.57 17.86 13.11
Rate ratiob
Type 2 vs. type 1 NC 3.55 1.57 1.94 2.61 NC 2.04
95% CI 1.42–8.62 1.01–2.43 1.04–3.62 0.86–7.93 1.50–2.78
P value 0.005 0.02 0.001 0.07 0.001
aAbbreviations are: CI, confidence interval; NC, not calculated; in these patients incidence density of diabetic nephropathy in type 1 diabetic patients during the
period was 0
bCalculated as the incidence density of diabetic nephropathy in type 2 diabetic patients divided by the incidence density in type 1 diabetic patients during the
same period
diagnosis, age at first visit, age at final examination, and
postpubertal duration of diabetes were comparable be-
tween the type 1 and type 2 diabetic patients. Body
mass index and blood pressure levels were higher, and
glycosylated hemoglobin (HbA1c) levels were lower in
patients with type 2 diabetes than in those with type 1
diabetes. Thirty-six percent of the type 2 diabetic patients
were treated with insulin. However, their serum C-pep-
tide levels were apparently preserved as compared with
the levels in the type 1 diabetic patients. The proportion
of patients who visited with referrals was similar for the
type 1 and type 2 diabetic patients (71%, 95% CI, 67 to
75% vs. 66%, 95% CI, 62 to 69%). The proportion of
patients with a family history of diabetes in first-degree
Fig. 2. Cumulative incidence of diabetic nephropathy according to relatives was 24% (95% CI, 21 to 27%) in the type 1
postpubertal duration of diabetes in patients with type 1 (j) and type
and 56% (95% CI, 53 to 59%) in the type 2 diabetic2 (d) diabetes diagnosed before the age of 30. Patients with type 2
diabetes had a significantly higher incidence of nephropathy than those patients.
with type 1 diabetes (P , 0.0001).
End points of the observation
For a total of 9357 person-years in type 1 diabetes, end
points of the observation were development of diabeticwas similar for the type 1 and type 2 diabetic patients.
nephropathy for 55 patients (791 person-years), the endThe distribution of patients according to the age at diag-
of follow-up without nephropathy for 447 patients (7403nosis of diabetes differed for the type 1 and type 2 dia-
person-years), death without nephropathy for 12 patientsbetic patients. However, for three subgroups based on
(173 person-years), and discontinued visits for 106 pa-the decade in which diabetes was diagnosed (that is, at
ages 0 to 9, 10 to 19, and 20 to 29 years), the age at tients (990 person-years). For a total of 10,917 person-
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Table 3. Incidence of diabetic nephropathy in young patients with type 1 and type 2 diabetes, by age at diagnosis of diabetesa
Age at diagnosis of diabetes years
0–9 10–19 20–29
Type 1
N new cases 14 25 16
Person-years of postpubertal duration 2875 3771 1914
Incidence density (/1000 person-years) 4.87 6.63 8.36
Type 2
N new cases 2 37 104
Person-years of postpubertal duration 78 2974 7855
Incidence density (/1000 person-years) 25.53 12.44 13.24
Rate ratiob
Type 2 vs. type 1 (95% CI) 5.24 1.88 1.58
95% CI 1.19–23.05 1.13–3.12 1.01–2.67
P value 0.04 0.003 0.04
aCI denotes confidence interval
bCalculated as the incidence density of diabetic nephropathy in type 2 diabetic patients divided by the incidence density in type 1 diabetic patients
Table 4. Incidence of diabetic nephropathy in young patients with type 1 and type 2 diabetes, by calendar year at onset of diabetesa
Calendar year at diagnosis of diabetes
1965–69 1970–74 1975–79 1980–84
Type 1
N new cases 13 18 13 7
Person-years of postpubertal diabetes 1224 1811 2058 1928
Incidence density (/1000 person-years) 10.62 9.94 6.32 3.63
Rate ratiob (vs. calendar year 1965–69) 1.0 0.94 0.60 0.34
95% CI 0.46–1.92 0.28–1.29 0.14–0.85
P value NS NS 0.002
Type 2
N new cases 29 47 41 22
Person-years of postpubertal diabetes 1713 2208 2659 2199
Incidence density (/1000 person-years) 12.38 21.29 15.42 9.98
Rate ratiob (vs. calendar year 1965–69) 1.0 1.26 0.91 0.59
95% CI 1.13–1.41 0.57–1.46 0.34–1.03
P value 0.02 NS NS
Rate ratioc
Type 2 vs. type 1 1.17 2.14 2.44 2.74
95% CI 0.61–2.25 1.24–3.68 1.31–4.55 1.17–6.41
P value NS 0.002 0.002 0.005
aCI denotes confidence interval; NS denotes not significant; Person-years were calculated until 20 years of postpubertal duration to compensate for the short
observation of the recently diagnosed group for comparing the effect of calendar year at diagnosis of diabetes
bCalculated as the incidence density of diabetic nephropathy in each group (that is, calendar year at diagnosis of diabetes between 1970 and 1974, 1975 and 1979,
and 1980 and 1984) divided by the incidence density of patients with diabetes diagnosed between 1965 and 1969 as reference
cCalculated as the incidence density of diabetic nephropathy in type 2 diabetic patients divided by the incidence density in type 1 diabetes
years in type 2 diabetes, end points of the observation tically significant and persistently high incidence of ne-
phropathy in patients with type 2 compared with thosewere development of diabetic nephropathy for 143 pa-
tients (1867 person-years), the end of follow-up without with type 1 diabetes. The rate ratio for type 2 diabetic
patients relative to type 1 diabetic patients was 2.04 (95%nephropathy for 403 patients (6464 person-years), death
without nephropathy for 3 patients (44 person-years), CI, 1.50 to 2.78).
The cumulative incidence of nephropathy after 30and discontinued visits for 409 patients (2542 person-
years). years of postpubertal diabetes was significantly higher
(P , 0.0001) for patients with type 2 diabetes (44.4%,
Incidence density of diabetic nephropathy in type 1 95% CI, 37.0 to 51.8%) than for those with type 1 diabe-
and type 2 diabetes tes (20.2%, 95% CI, 14.9 to 25.8%; Fig. 2). Provided that
the type 2 diabetic patients who discontinued their clinicThe incidence density of diabetic nephropathy was
visits without nephropathy had no nephropathy until thecalculated for five-year periods on the basis of both the
final date of this study (March 1997), it still would haveentire duration of diabetes and the postpubertal duration
of diabetes (Table 2). Both calculations revealed a statis- remained significantly higher (P , 0.0001) for the pa-
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Table 5. Estimated cumulative incidence of diabetic nephropathy in the Poisson multivariate regression models
Postpubertal duration of diabetes years
5 10 15 20
Type 1
Diagnosed between 1965 and 1969
Cumulative incidence % 0 3.4 22.4 34.2
95% CI 1.5–8.3 13.3–37.3 20.9–53.7
Diagnosed between 1980 and 1984
Cumulative incidence % 0 1.1 7.7 12.3
95% CI 0.5–2.6 4.2–14.0 6.5–23.1
Type 2
Cumulative incidence % 2.2 9.7 23.0 35.9
95% CI 1.4–3.7 6.8–13.8 17.3–30.3 28.1–45.3
CI denotes confidence interval. Covariates considered were sex, age at diagnosis of diabetes, calendar year at diagnosis of diabetes, observation year (postpubertal
duration of diabetes). The quadratic term of observation year was necessary to get an adequate fit to data. The effect of calendar year was significant only for type
1 diabetic patients. The final model included only the linear term of observation year, the quadratic term of observation year and the calendar year of diagnosis as
significant covariates.
Fig. 3. Cumulative incidence of diabetic nephropathy in patients with early-onset type 1 (A) and type 2 (B) diabetes, according to the calendar
year of diagnosis. Each asterisk denotes a significant difference in incidence (P , 0.05 with log-rank test) between the group indicated and the
group with diagnosis of diabetes between 1965 and 1969.
tients with type 2 diabetes (32.9%, 95% CI, 27.3 to whereas the incidence among the patients with type 2
diabetes remained persistently high. Patients who devel-38.5%) than for those with type 1 diabetes. The cumula-
tive incidences were similar for males and females in oped type 1 diabetes between 1980 and 1984 had a sig-
nificantly lower incidence (3.63 out of 1000 person-years)both types. The cumulative incidences were also similar
between those who visited with and without referrals than those who developed type 1 diabetes between 1965
and 1969 (10.62 out of 1000 person-years, rate ratio 0.34,and between those with and without a family history of
diabetes, in both types. P 5 0.002). The rate ratio for patients with type 2 diabe-
tes diagnosed between 1965 and 1969 relative to that forAnalysis of the incidence of diabetic nephropathy in
three groups according to the age at diagnosis of diabetes patients with type 1 diabetes diagnosed in the same pe-
riod was 1.17 (95% CI, 0.61 to 2.25; Table 4). The raterevealed a consistently higher incidence of nephropathy
in the patients with type 2 diabetes than in the patients ratio for the type 2 diabetic patients relative to the type
1 diabetic patients increased during the past two decades,with type 1 diabetes (Table 3).
The effect of the calendar year at diagnosis on the being 2.74 (95% CI, 1.17 to 6.41) in the patients with type
2 diabetes diagnosed between 1980 and 1984 relative toincidence of nephropathy is shown in Tables 4 and 5.
The incidence of nephropathy among the patients with the patients with type 1 diabetes diagnosed in the same
period.type 1 diabetes declined during the past two decades,
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Table 6. Clinical features of patients who did and did not develop nephropathy
Developed nephropathy Did not develop nephropathy P values
Type 1
Male % (95% CI) 30.1 (19.1–44.8) 39.3 (35.2–43.3) NS
Age at diagnosis of diabetes years 15.367.1 14.067.5 NS
HbA1c at first visit % 10.362.0 9.461.9 0.0002
Systolic blood pressure at first visit mm Hg 122616 112611 0.003
Diastolic blood pressure at first visit mm Hg 77610 7069 0.0001
Age at diagnosis of nephropathy or at end pointa years 29.767.2 29.268.3 NS
Type 2
Male % (95% CI) 55.2 (47.1–63.4) 55.3 (51.9–58.8) NS
Age at diagnosis of diabetes years 23.165.0 22.965.3 NS
HbA1c at first visit % 9.662.1 8.562.2 ,0.0001
Systolic blood pressure at first visit mm Hg 122619 116616 0.04
Diastolic blood pressure at first visit mm Hg 78611 74611 0.006
Age at diagnosis of nephropathy or at end pointa years 36.267.2 34.069.9 NS
Plus-minus values are mean 6 SD.
aDefinition of the end point is described in the method
Fig. 4. Comparison of the impact of risk factors on incidence density of diabetic nephropathy between type 1 (h) and type 2 ( ) diabetes.
Figure 3 showed the cumulative incidence of nephrop- person-years for type 1 diabetes were used for model
fitting. The final models included only the linear termathy in patients with early-onset type 1 (Fig. 3A) and
type 2 (Fig. 3B) diabetes, according to the year of diagno- of the observation year, the quadratic term of the obser-
vation year, and the calendar year of diagnosis as signifi-sis. The cumulative incidence was significantly lower in
patients with type 1 diabetes diagnosed between 1975 cant factors, which corresponded to the results of crude
analyses. The quadratic term was necessary to get anand 1979 and between 1980 and 1984, than in those with
type 1 diabetes diagnosed between 1965 and 1969. adequate fit. The effect of calendar year was significant
for only type 1 diabetic patients and was included as aFor simultaneously analyzing the effect of multiple
factors, multivariate Poisson log-linear models were fit- linear term. Models were fitted to type 1 and type 2
diabetes separately because parameters were entirelyted to the data. As covariates, sex, age at diagnosis of
diabetes, calendar year of diagnosis, and observation different. Predicted cumulative incidences were calcu-
lated based on fitted models, and confidence intervalsyear (postpubertal duration of diabetes) were consid-
ered. Simple models that allowed an interpretation con- were calculated using asymptomatic variance matrices
of the estimated parameters.sistent with that of a crude analysis could not be obtained
if we included patients who were diagnosed before age The estimated cumulative incidence from the Poisson
regression models after 20 years of postpubertal diabetes10 because of the complicated interaction among age at
diagnosis, year of diagnosis, and observation year. We declined from 34.2% (95% CI, 20.9 to 53.7%) in the
patients with type 1 diabetes diagnosed between 1965therefore deleted those patients and used the observa-
tion after 20 years for increasing the reliability of predic- and 1969 to 12.3% (95% CI, 6.5 to 23.1%) in those
with type 1 diabetes diagnosed between 1980 and 1984,tion based on the models. In all, 128 events in 10,791
person-years for type 2 diabetes and 44 events in 6288 whereas it remained unchanged among the patients with
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type 2 diabetes and was 35.9% (95% CI, 28.1 to 45.3%; cause of the lower frequencies of symptoms early in
the disease. A lack of awareness of diabetes and itsTable 5).
complications is unique to type 2 diabetes and could be
Risk analysis for diabetic nephropathy in type 1 and responsible for such patients developing diabetic ne-
type 2 diabetes phropathy and ESRF [17, 22, 42]. Interestingly, the inci-
dence density of diabetic nephropathy in our patientIn both type 1 and type 2 diabetes, patients who devel-
oped nephropathy showed significantly higher levels of population declined after 15 to 20 years of diabetes dura-
tion in both types of diabetes. The finding has beenHbA1c and blood pressure than those who did not (Ta-
ble 6). The incidence of nephropathy increased with in- confirmed in type 1, but not in type 2 diabetes.
Clinical features such as sex and age at diagnosis ofcreasing HbA1c values and blood pressure levels in both
types of diabetes (Fig. 4). The incidence of nephropathy diabetes were different between the two types. The dif-
ferences are not due to a selection bias, as other reportswas higher in patients with type 2 diabetes than those
with type 1 diabetes at every stratum of HbA1c. Patients include more female Japanese patients with type 1 diabe-
tes [28], and patients with type 2 diabetes were older atwith type 1 diabetes and the highest blood pressure levels
showed a significantly higher incidence of nephropathy diagnosis than those with type 1 diabetes in a population
with early-onset diabetes [16]. The high incidence ofthan those with type 2 diabetes and the same blood
pressure value (P # 0.05). nephropathy for patients with type 2 diabetes shown in
our study is unlikely to be affected by these different
features, since the analysis according to the sex and age
DISCUSSION
at diagnosis of diabetes showed the same results (Table
This study did not aim at investigating the effects of 3). True duration of diabetes may be longer than the
putative risks (such as glycemic control, blood pressure, known duration in type 2 diabetes, but the difference
or lipid profiles on the development of diabetic nephrop- between the two in the present study is presumed to be
athy), but aimed at determining associations of the type less than a few years because type 2 diabetes rarely
of diabetes and year of diagnosis with the incidence of occurs before the age of 15. Provided that patients with
nephropathy under the conditions that: (1) both type 1 type 2 diabetes had a period of few years of diabetes
and type 2 diabetes occur in the young homogeneous before the diagnosis, it could not have accounted for the
population in Japan; (2) direct comparison was made significant high incidence of nephropathy in patients with
within the same unit between type 1 and type 2 diabetes; type 2 compared with those with type 1 diabetes.
(3) type of diabetes was carefully defined; (4) referral Ethnicity profoundly affects the incidence of diabetes
bias was evaluated; and (5) alternative causes of protein- as well as its vascular complications. The results of the
uria were excluded. The study showed the incidence of present study showed that type 2 diabetes occurred as
nephropathy to be twice as high in the patients with type early as the teens in our Japanese population, and that
2 as in the patients with type 1 in early-onset diabetes. the incidence of diabetic nephropathy in early-onset type
The incidence of nephropathy was not influenced by 2 diabetic patients was extraordinarily higher than that
gender, referral, and existence of diabetes in first-degree in type 1 diabetic patients in Japan. The high incidence
relatives. While the incidence of type 1 diabetes has of diabetic nephropathy in type 2 diabetic patients com-
decreased in our patient population during the past two pared with type 1 diabetic patients in this study is consis-
decades, type 2 diabetes has remained persistently high. tent with the findings of Cowie et al [3]. They demon-
Consequently, the rate ratio for the incidence of ne- strated a high and increasing incidence of diabetic ESRF
phropathy in type 2 diabetic patients relative to type 1 among black patients with type 2 diabetes as compared
diabetic patients has become more prominent in those with black patients with type 1 diabetes, although they
young, recently diagnosed diabetic patients in Japan. The neither investigated the onset of diabetic nephropathy
increasing rate ratio for the incidence of nephropathy in nor included patients with type 1 and type 2 diabetes of
type 2 diabetic patients relative to type 1 diabetic patients a comparable age. That study clearly revealed an ethnic
suggests that we will see a further increase in ESRF in difference between whites and blacks for the incidence
patients with type 2 diabetes in the future. This situation of diabetic ESRF, particularly in type 2 diabetes. Eth-
calls for urgent, intense educational efforts in the medical nicity may be one reason for the high incidence of dia-
community and the general population. Such efforts betic nephropathy among Japanese patients with early-
could save lives and lead to considerable economic sav- onset type 2 diabetes. While it appears that the incidence
ings, not only in type 1 [41] but also in type 2 diabetes. of diabetic nephropathy in patients with type 2 diabetes
The increased incidence of diabetic nephropathy in varies markedly according to ethnicity, this is not neces-
type 2 diabetic patients was found within 10 years after sarily the case for type 1 diabetes.
the diagnosis of diabetes. This may be explained by the Our study demonstrates that the incidence of diabetic
nephropathy in Japanese patients with type 1 diabetessystematic delay in the diagnosis of type 2 diabetes be-
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has decreased with the increasing calendar year at diag- higher (P , 0.0001) for the patients with type 2 diabetes
than for those with type 1 diabetes (data not shown).nosis of diabetes. This confirms the finding reported by
Bojestig et al that the cumulative incidence of nephropa- This suggests that type 2 diabetes is the major cause of
nephropathy in early-onset diabetes in Japan.thy in type 1 diabetes has decreased substantially during
the past two decades [18]. We were unable to clarify the In conclusion, the present study demonstrates signifi-
cant differences in the incidence of diabetic nephropathyreason for the declining incidence of nephropathy in this
study; however, it is speculated that metabolic regulation according to the type of diabetes and the year of diagno-
sis in early-onset diabetes in Japan. Such an analysis,and systemic blood pressure control, both of which evi-
dently affected the development of nephropathy (Table particularly in the non-Caucasian population, is awaited.
Diabetic nephropathy and progression to ESRF in type6 and Fig. 4), have been improved in recent years and
thus reduced the incidence in patients with type 1 diabe- 2 diabetes should be preventable through metabolic con-
trol [45–47], control of blood pressure [26, 48], use oftes. The effects of these two factors on inhibiting ne-
phropathy have been supported by prospective and/or angiotensin-converting enzyme inhibitors [26, 49, 50],
protein restriction [51], and discontinuation of smokingobservational studies both in type 1 and type 2 diabetes
[26]. The increasing prevalence of type 2 diabetes [52][27, 43–51]. For patients with type 1 diabetes, regular
and of ESRF in type 2 diabetic patients worldwide [3,clinic visits are mandatory, which may induce better met-
8–12, 21–25] urgently demands programs for prevention ofabolic and blood pressure control; thus, this may have
diabetic nephropathy, especially in a high-risk population.caused a cumulative decline in the incidence of nephrop-
athy with increasing calendar year at diagnosis of diabe-
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